In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The FTC Takes a Closer Look at Consolidation

Executive Summary

The Federal Trade Commission's objections to the Abbott/Alza merger sank the deal--despite the companies' attempt to satisfy the FTC with a divestiture of the product at issue, Viadur. The implications: an increasingly aggressive FTC, with a much stricter sense of what constitutes anti-competitiveness, may require much different remedies from merging companies. But they're not saying what.

You may also be interested in...

Your Friend, the FTC: Nastech Solves a Knotty Anti-Trust Problem

When the FTC forced Pfizer/Pharmacia to divest Nastech's nasal apomorphine--a potential competitor of Pfizer's Viagra--Nastech managed what may be a unique solution: it got the product back, with additional financing-and in so doing, solved the very different problems of Pharmacia, Pfizer, the FTC, and itself.

J&J's $13 Billion Gamble on Alza

J&J is paying a lot to buy Alza, nearly twice what Abbott had been willing to pay two years before. It's convinced that Alza's current drugs--mid-sized products today--can be blockbusters. Its gamble: that it can make Alza's modest sized drugs into blockbusters; and--for the first time in the drug industry--to make a captive drug delivery capability into a productive R&D engine.

BMS's Rebloyzl Data Supports Adding Less Severe Patients To Label

Adding non-transfusion-dependent anemia patients to the Reblozyl label is a key strategy for the product, which BMS expects to reach $4bn in annual sales.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts